Media information Vifor Pharma

Under Media information, you will find more information specific to Vifor Pharma Business unit.

Vifor Pharma continues commitment to raise awareness of iron deficiency

Monday, 20 February 2017  

Vifor Pharma and ChemoCentryx Announce Expansion of Avacopan Agreement for Rare Renal Diseases 

Tuesday, 14 February 2017  

Vifor Pharma and ChemoCentryx Announce Expansion of Kidney Health Alliance to Include CCX140 to Treat Renal Diseases 

Friday, 23 December 2016  

EFFECT-HF demonstrates a significantly beneficial effect of Ferinject® on exercise capacity among patients with chronic heart failure and iron deficiency – confirms findings of previous studies 

Wednesday, 7 December 2016  

Vifor Pharma leads initiatives to raise awareness of Iron Deficiency – 2nd Global Iron Deficiency Day on November 26, 2016 

Thursday, 24 November 2016  

Swissmedic approves ALOXI® for use in the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) in Children in Switzerland - Swiss approval of ALOXI® for paediatric use follows EMA approval in February 2015 and FDA approval in May 2014 -

Tuesday, 25 October 2016  

Vifor Pharma expands ESA product portfolio with rights to commercialise Pfizer’s proposed epoetin alfa biosimilar, Retacrit™, in the US dialysis market 

Tuesday, 24 May 2016  

The 2016 ESC heart failure guidelines strongly recommend Ferinject® for the treatment of iron deficiency in patients with systolic heart failure 

Monday, 23 May 2016  

Vifor Pharma Licenses Rights to Commercialize ChemoCentryx’s Orally-Administered Complement 5aR Inhibitor CCX168 for Orphan and Rare Renal Diseases in Europe and Certain Other Major Markets 

Tuesday, 10 May 2016  

Vifor Pharma appoints Colin Bond as Chief Financial Officer 

Tuesday, 10 May 2016  

Contact

Galenica Ltd.

Media Relations
Untermattweg 8
CH-3027 Bern

Phone:
+41 58 852 85 17
Fax:
+41 58 852 85 58

Send link

Send as link



Links

  •